timolumab   Click here for help

GtoPdb Ligand ID: 9097

Synonyms: 8c10 | BTT-1023 | BTT1023 | r8c10 | SI-3106 | SI-636
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tmolumab is a fully human anti-AOC3 (amine oxidase copper containing 3, VAP1) monoclonal antibody being investigated for its immunomodulatory action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US7897149, in particular with the recombinant fully human antibody BTT-1023 named therein [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Timolumab (with research code BTT1023) is being evaluated in Phase 2 clinical trial NCT02239211, for its potential to treat patients with primary sclerosing cholangitis, an uncommon and progressive disease of the bile ducts characterised by inflammation and obliterative fibrosis. Phase 1 studies for RA and psoriasis have been completed (2010/11).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02239211 A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2 Interventional University of Birmingham